4.7 Article

Activation of nuclear receptor PXR impairs glucose tolerance and dysregulates GLUT2 expression and subcellular localization in liver

Journal

BIOCHEMICAL PHARMACOLOGY
Volume 148, Issue -, Pages 253-264

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2018.01.001

Keywords

PXR; GLUT2; GCK; Impaired glucose tolerance; Diabete

Funding

  1. Academy of Finland [286743, 276747]
  2. Novo Nordisk Foundation [NNF14OC0010653, NNF15OC0015846]
  3. Duodecim Society of Oulu
  4. Finnish Medical Foundation
  5. Finnish Foundation for Cardiovascular Research
  6. Diabetes Research Foundation
  7. Novo Nordisk Fonden [NNF14OC0010653, NNF15OC0015846] Funding Source: researchfish

Ask authors/readers for more resources

Pregnane X receptor (PXR) is a nuclear receptor that senses chemical environment and is activated by numerous clinically used drugs and environmental contaminants. Previous studies have indicated that several drugs known to activate PXR appear to induce glucose intolerance. We now aimed to reveal the role of PXR in drug-induced glucose intolerance and characterize the mechanisms involved. We used PXR knockout mice model to investigate the significance of this nuclear receptor in the regulation of glucose tolerance. PXR ligand pregnenolone-16a-carbonitrile (PCN) impaired glucose tolerance in the wild type mice but not in the PXR knockout mice. Furthermore, DNA microarray and bioinformatics analysis of differentially expressed genes and glucose metabolism relevant pathways in PCN treated primary hepatocytes indicated that PXR regulates genes involved in glucose uptake. PCN decreased the expression of glucose transporter 2 (GLUT2) in mouse liver and in the wildtype mouse hepatocytes but not in the PXR knockout cells. Data mining of published chromatin immunoprecipitation-sequencing results indicate that Glut2 gene is a direct PXR target. Furthermore, PCN induced internalization of GLUT2 protein from the plasma membrane to the cytosol in the liver in vivo and repressed glucose uptake in the primary hepatocytes. Our results indicate that the activation of PXR impairs glucose tolerance and thus PXR represents a novel diabetogenic pathway. PXR activation dysregulates GLUT2 function by two different mechanisms. These findings may partly explain the diabetogenic effects of medications and environmental contaminants. (C) 2018 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

Rifampicin induces the bone form of alkaline phosphatase in humans

Heba Nabil, Outi Kummu, Petri Lehenkari, Jaana Rysa, Juha Risteli, Jukka Hakkola, Janne Hukkanen

Summary: Rifampicin treatment induces bone form alkaline phosphatase in the serum of healthy human volunteers by activating PXR. Further studies are needed to establish the mechanism of this novel finding.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2022)

Article Nutrition & Dietetics

Analysis of the SYSDIET Healthy Nordic Diet randomized trial based on metabolic profiling reveal beneficial effects on glucose metabolism and blood lipids

Gozde Gurdeniz, Matti Uusitupa, Kjeld Hermansen, Markku J. Savolainen, Ursula Schwab, Marjukka Kolehmainen, Lea Brader, Lieselotte Cloetens, Karl-Heinz Herzig, Janne Hukkanen, Fredrik Rosqvist, Stine Marie Ulven, Ingibjorg Gunnarsdottir, Inga Thorsdottir, Matej Oresic, Kaisa S. Poutanen, Ulf Riserus, Bjorn Akesson, Lars Ove Dragsted

Summary: This study characterized a multicenter randomized controlled trial comparing a healthy Nordic diet (HND) to a control diet (CD) using plasma and urine metabolic profiles and associated them with cardiometabolic markers. The results showed that the metaboic profiles of blood and urine were able to distinguish between the two diets and were associated with glucose metabolism and lipoproteins.

CLINICAL NUTRITION (2022)

Article Cell Biology

Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia

Mikko Karpale, Janne Hukkanen, Jukka Hakkola

Summary: Atherosclerosis is a global health concern with high total and LDL cholesterol as the main risk factors. Understanding the factors influencing an individual's cholesterol levels during the formation of arteriosclerotic plaques is crucial. Activation of pregnane X receptor (PXR) has been shown to induce hypercholesterolemia and may play a role in drug-induced high cholesterol levels.

CELLS (2022)

Article Medicine, General & Internal

Long-term metabolic fate and mortality in obesity without metabolic syndrome

Aki Juhani Karajamaki, Arto Korkiakoski, Janne Hukkanen, Y. Antero Kesaniemi, Olavi Ukkola

Summary: The presence of metabolic syndrome (MetS), but not obesity only, entails a greater risk of mortality and cardiovascular diseases. The risk of atrial fibrillation is increased only in subjects with both obesity and MetS. Obesity without MetS tends to progress eventually to obesity with MetS.

ANNALS OF MEDICINE (2022)

Article Endocrinology & Metabolism

Streptozotocin-induced Diabetes Represses Hepatic CYP2R1 Expression but Induces Vitamin D 25-Hydroxylation in Male Mice

Mahmoud-Sobhy Elkhwanky, Outi Kummu, Jukka Hakkola

Summary: Research shows that in a mouse model of type 1 diabetes, suppression of hepatic Cyp2r1 expression does not lead to reduced hepatic vitamin D 25-hydroxylase activity and vitamin D deficiency, likely due to induction of other vitamin D 25-hydroxylase enzymes in response to diabetes.

ENDOCRINOLOGY (2022)

Article Cardiac & Cardiovascular Systems

Pregnane X Receptor-4β-Hydroxycholesterol Axis in the Regulation of Overweight- and Obesity-Induced Hypertension

Roosa Rahunen, Outi Kummu, Vesa Koivukangas, Heidi Hautajarvi, Jukka Hakkola, Jaana Rysa, Janne Hukkanen

Summary: This study found that activation of PXR can increase blood pressure, while elevated 4-beta hydroxycholesterol in circulation can lower blood pressure. It was also found that 4-beta hydroxycholesterol in the blood is negatively correlated with blood pressure in obese patients and healthy volunteers. This study reveals a new hypertension regulating pathway associated with overweight and obesity.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

Article Pharmacology & Pharmacy

Effects of rifampicin on porphyrin metabolism in healthy volunteers

Hanna Tolonen, Sirpa Ranta, Esa Hamalainen, Raili Kauppinen, Janne Hukkanen

Summary: This study investigated the effects of PXR activation on porphyrin metabolism and found that rifampicin increased the excretion of certain urinary porphyrin metabolites and decreased faecal protoporphyrin IX excretion. This suggests that increased excretion may serve as a hepatoprotective shunt when haem synthesis or porphyrin levels are increased.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2023)

Review Toxicology

Adverse outcome pathway for pregnane X receptor-induced hypercholesterolemia

Anna Itkonen, Jukka Hakkola, Jaana Rysa

Summary: Pharmaceuticals and environmental contaminants contribute to hypercholesterolemia by activating pregnane X receptor (PXR). PXR activation disrupts lipid metabolism and promotes hypercholesterolemia through multiple mechanisms. This novel toxicity pathway is of great concern and requires further attention.

ARCHIVES OF TOXICOLOGY (2023)

Article Endocrinology & Metabolism

Pregnane X receptor activation remodels glucose metabolism to promote NAFLD development in obese mice

Mikko Karpale, Outi Kummu, Olli Karkkainen, Marko Lehtonen, Juha Napankangas, Uta M. Herfurth, Albert Braeuning, Jaana Rysa, Jukka Hakkola

Summary: This study found that both obesity and chemical exposure can induce non-alcoholic fatty liver disease (NAFLD), and the Pregnane X Receptor (PXR) plays a key role in liver glucose and lipid metabolism. Activation of PXR worsened obesity-induced liver steatosis and impaired hepatic insulin sensitivity. The research also suggests that obese individuals may be more susceptible to harmful metabolic effects of PXR-activating drugs and environmental chemicals.

MOLECULAR METABOLISM (2023)

Article Endocrinology & Metabolism

Mobile health behaviour change support system as independent treatment tool for obesity: a randomized controlled trial

Jaakko O. Markkanen, Noora Oikarinen, Markku J. Savolainen, Heta Merikallio, Ville Nyman, Ville Salminen, Teppo Virkkula, Pasi Karppinen, Harri Oinas-Kukkonen, Janne Hukkanen

Summary: This study aimed to investigate the effectiveness of a mobile health behaviour change support system (mHBCSS) as a stand-alone treatment for obesity. The results showed that mHBCSS led to weight reduction and maintenance, with high adherence rates.

INTERNATIONAL JOURNAL OF OBESITY (2023)

Article Pharmacology & Pharmacy

Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib

Paola Orlandi, Marta Banchi, Francesca Vaglini, Marco Carli, Stefano Aringhieri, Arianna Bandini, Carla Pardini, Cristina Viaggi, Michele Lai, Greta Ali, Alessandra Ottani, Eleonora Vandini, Patrizia Guidi, Margherita Bernardeschi, Veronica La Rocca, Giulio Francia, Gabriella Fontanini, Mauro Pistello, Giada Frenzilli, Daniela Giuliani, Marco Scarselli, Guido Bocci

Summary: This study investigates the role of MC4R in melanoma and the use of the selective antagonist ML in combination with vemurafenib. The results show that ML can inhibit melanoma cell proliferation and induce apoptosis through the inhibition of ERK1/2 phosphorylation and reduction of BCL-XL expression. The combination of vemurafenib and ML exhibits a synergistic effect in vitro and inhibits tumor growth in vivo without causing adverse effects.

BIOCHEMICAL PHARMACOLOGY (2024)

Article Pharmacology & Pharmacy

Cardiac human bitter taste receptors contain naturally occurring variants that alter function

Conor J. Bloxham, Katina D. Hulme, Fabrizio Fierro, Christian Fercher, Cassandra L. Pegg, Shannon L. O'Brien, Simon R. Foster, Kirsty R. Short, Sebastian G. B. Furness, Melissa E. Reichelt, Masha Y. Niv, Walter G. Thomas

Summary: Bitter taste receptors (T2Rs) are a type of G protein-coupled receptors that allow humans to detect aversive and toxic substances. This study characterized the functional properties of previously identified T2Rs in human cardiac tissues and their naturally occurring polymorphisms. The results showed differences in signaling among different T2R variants, and revealed a potential association between the T2R50 Tyr203 variant and cardiovascular disease.

BIOCHEMICAL PHARMACOLOGY (2024)

Article Pharmacology & Pharmacy

Carfilzomib suppressed LDHA-mediated metabolic reprogramming by targeting ATF3 in esophageal squamous cell carcinoma

Lu Chen, Huanying Shi, Wenxin Zhang, Yongjun Zhu, Haifei Chen, Zimei Wu, Huijie Qi, Jiafeng Liu, Mingkang Zhong, Xiaojin Shi, Tianxiao Wang, Qunyi Li

Summary: This study demonstrates that Carfilzomib exhibits potent anti-tumor activity against esophageal squamous cell carcinoma (ESCC) by triggering mitochondrial apoptosis and reprogramming cellular metabolism. It has been identified that activating transcription factor 3 (ATF3) plays a crucial role as a cellular target in ESCC cells treated with Carfilzomib. Overexpression of ATF3 effectively counteracts the effects of Carfilzomib on ESCC cell proliferation, apoptosis, and metabolic reprogramming. Furthermore, ATF3 mediates the anti-tumor activity of Carfilzomib, suggesting its potential as a therapeutic agent for ESCC.

BIOCHEMICAL PHARMACOLOGY (2024)

Review Pharmacology & Pharmacy

Ferroptosis resistance in cancer: recent advances and future perspectives

Xing Zhang, Xiang Li, Ran Xia, Hong-Sheng Zhang

Summary: This review summarizes recent progress on the mechanisms of ferroptosis resistance in cancer and highlights the role of redox status and metabolism. Combination therapy for ferroptosis has great potential in treating resistant malignant tumors.

BIOCHEMICAL PHARMACOLOGY (2024)